Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of schistosomiasis treatment in Tanzania
PACTR201612001914353Unknown
- Sponsor
- Muhimbili University of Health and Allied Sciences
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of praziquantel and dihydroartemisinin + piperaquine in schistosomiasis (2 arms), sponsored by Muhimbili University of Health and Allied Sciences. Primary endpoints: Schistosomiasis treatment outcome at 1 month and Schistosomiasis treatment outcome at 2 months. Status: unknown.
02
Drugs
praziquanteldihydroartemisinin + piperaquine
03
Conditions
schistosomiasis
Beyond the preview
Go deeper on PACTR201612001914353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201612001914353.